Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate

NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinical dose-optimization study conducted with a surrogate of its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at the 69th Scientific Sessions of the American Diabetes Association (ADA), which is continuing until June 9, 2009 in New Orleans, Louisiana.

The presentation (#297-OR), entitled "Dose Ranging Studies of an Anti-CD3 Antibody in NOD mice to Determine Minimum Effective Dose," was part of an Oral Session on Antigen-Specific and Non-Specific Regulation of Type 1 Diabetes. In the session, Dr. Devangi Mehta, Tolerx Senior Scientist, presented data demonstrating the effects of modified dosing regimens of the anti-CD3 monoclonal antibody in a commonly used non-obese diabetic (NOD) mouse model of autoimmune diabetes.

Tolerx researchers conducted dose-ranging studies to establish the minimum effective dose and to investigate pharmacodynamic (PD) parameters, including T-cell receptor (TCR) modulation, that correlate with efficacy in a preclinical model of diabetes. Evaluation of a dose of 8ug (0.0004mg/kg) of anti-CD3 antibody, a 30-fold reduction from previously investigated dosing regimens, induced up to 53% remission of diabetes, a response rate equivalent to those achieved with a 250ug (0.0125mg/kg) dosing regimen in other studies. This result demonstrates that lower doses of anti-CD3 monoclonal antibody, causing partial TCR modulation, are efficacious in this model, and that high doses resulting in full TCR modulation are not required to achieve similar rates of remission.

These data, combined with a rigorous Phase 2 clinical development program assessing more than 10 dosing regimens, have led
'/>"/>

SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ANGELES , Aug. 27, 2014   Los ... now offers AcceleDent® Aura to patients who want to ... orthodontic care available at the OrthoSpaceship, all patients have ... better-looking teeth. This system can be used by most ... their rate of progress by using the AcceleDent® Aura ...
(Date:8/27/2014)... -- Decision Resources Group finds that the intense physician ... health system and hospital sector in recent years ... Le Bonheur Healthcare and Baptist Memorial Health Care pulling ... In addition, a national contract recently signed between Tenet ... in the Memphis market, sets ...
(Date:8/27/2014)... August 27, 2014 According ... Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current Trends, ... MarketsandMarkets, the global Dental Equipment Market is expected to ... in 2014, growing at a CAGR of 5.7% ... market data tables and 61 figures spread through ...
Breaking Medicine Technology:Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... Ten percent of cancer patients failed to fill their initial prescriptions ... today in the Journal of Oncology Practice ( JOP ... ). The study was based on an analysis conducted by Avalere ... 2007 to 2009. This study has also been accepted for presentation ...
... The Consumer Healthcare Products Association (CHPA), representing makers ... applauds the U.S. Food and Drug Administration (FDA) ... children the right amount of medicine. Today, the ... Committee recommended enhancing the labels of all OTC ...
Cached Medicine Technology:New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 2New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 3New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 4OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3
(Date:8/27/2014)... Holbrook, CP LP, has joined Fourroux Prosthetics, headquartered in ... experience in the prosthetics field. He graduated from ... Science degree with a major in biology and a ... in prosthetics at Northwestern University in Chicago, Illinois. , ... Fourroux,” says Keith Watson, owner of Fourroux. “His ...
(Date:8/27/2014)... For nearly two decades, audiences around the ... singers Deva Premal & Miten with their rapturous Nepali ... latest album in May, their 2014 MANTRAS FOR LIFE ... the globe, including Russia, Ukraine, Israel, Australia, the U.S., ... a new album and a new five-piece band, the ...
(Date:8/27/2014)... (HealthDay News) -- In a new study done from ... your blood pressure steadily increases if you ascend to ... widely used to treat high blood pressure was ineffective ... findings, reported online Aug. 27 in the European ... but those at sea level who have sleep apnea, ...
(Date:8/27/2014)... (HealthDay News) -- A new genetic discovery about Crohn,s ... bowel disorder, researchers report. The scientists pinpointed ... their genes work, and said these changes can be ... possibility of a simple diagnostic test for Crohn,s, the ... and suggest possible gene targets for new treatments, said ...
(Date:8/27/2014)... Princeton, NJ (PRWEB) August 27, 2014 ... revenue enhancement and protection services for hospitals, is pleased ... 2014 Inc. 5000 List of America’s Fastest-Growing Companies. The ... segment of the economy—America’s independent entrepreneurs. , "It's ... are honored to be included in this year's Inc. ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2
... Blue Cross Blue Shield of Michigan announced today that Kevin ... current vice president for products and marketing, will succeed Jeanne ... when Carlson retires at the end of February 2010. , ... and CEO of BCBSM, parent company of Blue Care Network. ...
... - Proposed 30-Year Lease Agreement Will Help Stevens Hospital Expand, ... Wash., Dec. 17 The Board of Commissioners for Public ... for Swedish to lease and assume management of Stevens Hospital ... agreements. The public is invited to a hearing in mid-January ...
... from physician, study finds , THURSDAY, Dec. 17 (HealthDay News) ... parents to place infants on their backs to go to ... SIDS, researchers have found. , Since the U.S. government launched ... infants placed on their backs at sleep time has increased ...
... checkout counters of clothing stores, gas stations -- and adding ... News) -- If you,re hungry while shopping for a new ... sell sweet or salty snacks, a new report finds. , ... far beyond grocery stores to hit most segments of the ...
... ... Fisher Theatre on Dec. 17 for the Detroit-area,premiere of the award-winning musical “Jersey Boys,” Beaumont ... , ... When the cast takes the stage at the Fisher Theatre on Dec. 17 for the ...
... might be more likely to try alcohol, illegal drugs ... believe that smoking cigarettes is riskier than using illicit ... , That perception may increase the likelihood that they,ll ... said. , "We are on the right track with ...
Cached Medicine News:Health News:Stevens Hospital to Affiliate with Swedish 2Health News:Stevens Hospital to Affiliate with Swedish 3Health News:Stevens Hospital to Affiliate with Swedish 4Health News:Doctor's Orders Influence Baby's Sleep Position 2Health News:Wide Array of Stores Now Sell High-Calorie Snacks 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Teens Think Smoking More Dangerous Than Drinking, Drugs 2
Inquire...
Inquire...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Inquire...
Medicine Products: